MAM
CPRX

Meeder Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Meeder Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$257K Buy
+10,392
New +$248K 0.01% 275
2025
Q3 		– Sell
-2,957
Closed -$64.2K – 836
2025
Q2 		$64.2K Sell
2,957
-6,484
-69% -$153K ﹤0.01% 342
2025
Q1 		$229K Sell
9,441
-2,392
-20% -$53.9K 0.02% 236
2024
Q4 		$247K Buy
11,833
+7,336
+163% +$158K 0.02% 205
2024
Q3 		$89.4K Hold
4,497
– – 0.01% 303
2024
Q2 		$69.7K Buy
+4,497
New +$70K ﹤0.01% 304
2023
Q1 		– Sell
-22
Closed -$409 – 659
2022
Q4 		$409 Sell
22
-75
-77% -$1.16K ﹤0.01% 755
2022
Q3 		$1K Buy
+97
New +$1.15K ﹤0.01% 1926
2021
Q4 		– Sell
-18,581
Closed -$99K – 1414
2021
Q3 		$99K Hold
18,581
– – 0.01% 897
2021
Q2 		$107K Hold
18,581
– – 0.01% 889
2021
Q1 		$85K Buy
+18,581
New +$73.8K ﹤0.01% 955
2020
Q4 		– Sell
-18,582
Closed -$55K – 1943
2020
Q3 		$55K Hold
18,582
– – ﹤0.01% 935
2020
Q2 		$86K Buy
18,582
+4,835
+35% +$21.7K 0.01% 792
2020
Q1 		$52K Buy
13,747
+7,255
+112% +$29.8K ﹤0.01% 891
2019
Q4 		$25K Buy
6,492
+3,100
+91% +$14.5K ﹤0.01% 1278
2019
Q3 		$19K Sell
3,392
-9,859
-74% -$52.5K ﹤0.01% 1329
2019
Q2 		$50K Buy
13,251
+11,548
+678% +$49.9K ﹤0.01% 954
2019
Q1 		$9K Sell
1,703
-32,534
-95% -$95.6K ﹤0.01% 1264
2018
Q4 		$67K Buy
34,237
+22,227
+185% +$63.6K 0.01% 742
2018
Q3 		$46K Sell
12,010
-4,502
-27% -$14.1K ﹤0.01% 799
2018
Q2 		$51.5K Buy
16,512
+14,200
+614% +$43.1K ﹤0.01% 749
2018
Q1 		$5K Buy
2,312
+1,286
+125% +$4.27K ﹤0.01% 1214
2017
Q4 		$3K Buy
+1,026
New +$3.39K ﹤0.01% 1420

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Meeder Asset Management's CPRX Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 10,392 shares worth $257K. The stake represents 0.01% of the portfolio and ranks #275 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in CPRX as recently as Q2 2025.

Meeder Asset Management first reported a position in CPRX in Q4 2017 and has held it in 23 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Meeder Asset Management held 10,392 shares of Catalyst Pharmaceutical worth $257K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Meeder Asset Management position in Q1 2026.
  • Catalyst Pharmaceutical made up 0.01% of Meeder Asset Management's portfolio in Q1 2026, its #275 holding.
  • Meeder Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 23 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.